Concepedia

Michael W. Dunne

MW

Statistics

Publications

60

Citations

5.2K

H-Index

37

Active since

1973

Affiliations

Pfizer (United States)(Current)

Fulcrum Therapeutics (United States)

University of California San Diego

Gates Foundation

Allergan (United States)

Michael W. Dunne is an author at Pfizer (United States) specializing in pharmacology, antimicrobial pharmacotherapy, and pharmacotherapy.

ORCID

Publications per year

1973–2025

60

Publications

60

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

Roy M. Gulick, Jacob Lalezari, James Goodrich et al. · New England Journal of Medicine · 2008 · 741 citations · Full text

, , +17

Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection

Helen W. Boucher, Mark Wilcox, George H. Talbot et al. · New England Journal of Medicine · 2014 · 425 citations · Full text

, , +16

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

Gerd Fätkenheuer, Mark Nelson, Adriano Lazzarin et al. · New England Journal of Medicine · 2008 · 361 citations · Full text

, , +17

Prophylaxis against Disseminated<i>Mycobacterium avium</i>Complex with Weekly Azithromycin, Daily Rifabutin, or Both

Diane V. Havlir, Michael P. Dubé, Fred R. Sattler et al. · New England Journal of Medicine · 1996 · 333 citations · Full text

, , +16

Azithromycin for the Secondary Prevention of Coronary Heart Disease Events

Christopher M. O’Connor, Michael W. Dunne, Marc A. Pfeffer et al. · JAMA · 2003 · 327 citations

, , +12

1–5 of 60